IP Library Granted Patent US 11,090,327
Granted Patent B2
US 11,090,327 · App. 16/295,073 · Granted Aug 17, 2021

Sulfated glycosaminoglycan biomaterials as proteoglycan mimics

Inventor: Thomas H. Jozefiak (Belmont, MA)
Assignee: Glycologix, LLC
A61K31/726A61K9/0019A61K47/61A61P13/10C07C317/08C08B15/005C08B37/0063C08B37/0072
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,090,327
App. No.
16/295,073
Granted
Aug 17, 2021
Kind
B2
Abstract

Polymer conjugates are provided that are capable of mimicking functions of natural proteoglycans found in the extracellular matrix of connective tissues. The polymer conjugates of the invention have utility in treating a subject suffering soft tissue conditions. Also provided are simple and scalable chemical processes for the preparation of the polymer conjugates of the invention.

Claims (11)

1. A water-soluble polymer conjugate having a bottlebrush-like architecture with a sulfated glycosaminoglycan (GAG) backbone and further comprising a plurality of sulfated GAG polymer chains, wherein each sulfated GAG polymer chain is linked to one or more sulfated GAG polymer chains via a linker derived from divinylsulfone, and wherein the polymer conjugate is soluble in aqueous solution and has a molecular weight that is 3X to 100X that of an individual, nonlinked sulfated GAG and that is between 15,000 Da to 1,000,000 Da.

2. The polymer conjugate of claim 1 , wherein the sulfated GAG is selected from the group consisting of chondroitin sulfate, heparan sulfate, dermatan sulfate, keratan sulfate, and combinations thereof.

3. The polymer conjugate of claim 1 , wherein the linker is randomly linked along a GAG polymer chain.

4. A method of preparing the conjugate of claim 1 , via sequential introduction of the sulfated GAG in a single reaction, comprising the steps of:

i) providing an aqueous sulfated GAG solution; and

ii) reacting the aqueous sulfated GAG solution with divinylsulfone under conditions where a small portion of the sulfated GAG is reacted with the full portion of linking agent; and

iii) adding the remaining portion of sulfated GAG to form a conjugate with bottlebrush-like architecture.

5. A method of claim 4 , wherein the molar ratio of GAG hydroxyl groups to divinylsulfone is 0.01 to 0.6.

6. A method of claim 4 , wherein the product of step (ii) is isolated.

7. A method of treating Interstitial Cystitis (IC) in a patient comprising the step of administering to the patient, a conjugate of claim 1 .

8. The method of claim 7 , wherein administration is intravesical instillation.

Assignments (2)
MERGER Recorded May 17, 2022
From: GLYCOLOGIX LLC
To: GLYCOLOGIX, INC.
Reel/Frame 059933/0346 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2019
From: JOZEFIAK, THOMAS H.
To: GLYCOLOGIX, LLC
Reel/Frame 048802/0016 →
Continuity (3)
Continuation PCTUS2017051799 · Sep 15, 2017
Provisional Application 62395805 · Sep 16, 2016
Related Publication 20190262386A1 · Aug 29, 2019